Introduction
TNF blockers have been the therapeutics of choice for nearly 15 years in patients with axial spondyloarthritis (axSpA, including both radiographic axSpA, also known as AS, and non-radiographic axial SpA, nr-axSpA) if conventional treatment fails. Only recently drugs targeting IL-17A have also been shown to be effective for these diseases [1, 2] . During the past decade, the Th17 axis has been shown to play an important role in the pathogenesis of animal models of autoimmune disease, indicating that it might also play a relevant role in the pathogenesis of immune mediated diseases in humans [3, 4] . Th17 cells produce IL-17 on stimulation with IL-23, but cells from the innate immune system also respond to IL-23 stimulation, probably not only by the secretion of IL-17 [3] . IL-23-independent production of IL-17 has also been reported [5] . Furthermore, it has been shown using tissue samples from AS patients that IL-17 seems to be more frequently produced by non-T cells than by T cells [6] .
Clinical trials performed over recent years in various chronic inflammatory diseases have revealed quite different responses on inhibition of IL-17, which were difficult to predict from the available pre-clinical data [7] . Here we discuss the possible consequences for the future treatment of axSpA. We concentrate on IL-17 blockers along with TNF blockers because only these two drug classes have proven efficacy in axSpA.
TNF and IL-17 blockade in axSpA
AxSpA is rather unique among the chronic inflammatory (rheumatic) diseases because until recently NSAIDs and TNF-blocking agents had been the only effective treatments. Conventional DMARDs and a variety of other biologics successfully used for the treatment of RA or other chronic inflammatory diseases are not effective in the majority of patients with axSpA [8] . Most recently the results of a small dose ranging trial with tofacitinib-a Janus kinase (JAK) 1 and 3 inhibitor-in AS have been published showing a moderate response for some of the doses tested compared with placebo, but not for all doses. However, more trials would be needed to evaluate the treatment effect of JAK inhibitors in axial SpA before JAK inhibitors can be included in a discussion on the best treatment targets in axSpA [9] .
Although all these newer drugs were tested in AS, it can be assumed that efficacy results can also be extrapolated to nr-axSpA. The good efficacy shown for TNF blockers for the treatment of AS, and recently also for nr-axSpA [7] , has been a breakthrough for the treatment of these diseases 15 years ago. Only recently it could be shown that the IL-17 inhibitor secukinumab was also effective-as the first post-TNF blocker biologic-in the treatment of AS [2] . By indirect comparison, secukinumab has about similar efficacy to TNF blockers, although a head to head trial has not yet been performed: an Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40 and ASAS partial remission was reached in 61%, 36% and 14% of the patients, respectively, receiving 150 mg secukinumab s.c. [2] as compared with response rates of 5864%, 4047% and 2023%, respectively, achieved with the five TNF blockers in the phase III trials (Table 1) . Of note, in contrast to TNF blocker studies (with the only exception of certolizumab pegol), where patients were anti-TNF naïve, about 40% of the patients in the secukinumab study (MEASURE-2) were anti-TNF experienced (including primary nonresponders, secondary non-responders and patients with intolerability/side effects related to anti-TNF therapy). In the subgroup of anti-TNF naïve patients, 68%, 43% and 18% demonstrated ASAS20, ASAS40 and ASAS partial remission responses, respectively, in the secukinumab 150 mg group [10] . In the anti-TNF experienced group, smaller proportions of patients reached clinical responses. Different from PsA [11] a dose of 300 mg secukinumab was not tested in the pivotal phase III trials in AS [2] (but in the MEASURE-3 trial that includes a 300 mg arm and which is ongoing-ClinicalTrials.gov ID: NCT02008916); therefore, it is not clear at the moment whether a higher dose than 150 mg might be superior for the treatment of AS, especially in anti-TNF non-responders. Secukinumab has not been tested in nr-axSpA yet but such a study is being currently performed (ClinicalTrials.gov ID: NCT02696031), also for another IL-17A inhibiting agent, ixekizumab (ClinicalTrials.gov ID: NCT02757352). Although it is difficult to compare side effects without head to head trials, there are no clear differences in the frequency of side effects if TNF-and IL-17-inhibitor trials are compared, although some of the specific side effects differ [8] .
There are currently no clear evidence-based recommendations for which of these biologics to start with in axSpA in case of failure of previous conventional therapies. The ASAS / European League Against Rheumatism (EULAR) management recommendations [1] for axSpA suggest starting normally with a TNF blocker before switching to an anti-IL-17 inhibitor or to a second TNF blocker. However, the preference for a TNF blocker as a first biologic is only based on a considerably greater and longer experience with TNF blockers, including safety data. The American College of Rheumatology (ACR) / Spondyloarthritis Research and Therapy Network (SPARTAN) [12] recommendations for axSpA have not yet included anti-IL-17 treatment because they were published before the IL-17 inhibitor secukinumab had been approved for the indication of AS in the USA. This clearly shows that more data on the relative role of TNF blockers and IL-17 inhibitors for the treatment of axSpA are urgently needed.
TNF and IL-17 blockade in PsA and other chronic inflammatory diseases
PsA is somewhat similar to axSpA regarding treatment options, although conventional and targeted DMARDs and other biologics than anti-TNF and anti-IL-17 have also shown some efficacy-in contrast to axial SpA [13] . TNF blockers and IL-17 inhibitors showed, similar to axSpA, rather similar responses by indirect and direct [14] comparisons. Thus, similar considerations to those presented here for axSpA could also apply to PsA, but will not be discussed in more detail in this article.
The relative role of TNF and IL-17 inhibition is different in the treatment of other chronic inflammatory diseases such as RA, psoriasis or Crohn's disease. In RA, IL-17 inhibition resulted at the most in a moderate response. Using secukinumab in the 300 mg dose ACR20/50/70 was reached in 54%/17%/5%, respectively, vs 36%/6%/0%, respectively, in the placebo group [15], at week 16, clearly not reaching the normally expected 60%/40%/20% response rates for an effective drug in RA [16] . Similarly, the IL-17 inhibitor ixekizumab in a dose of 80 mg every 2 weeks resulted only in 51%/26%/7% response rates vs 35%/9%/ 2% in the placebo group after 12 weeks of treatment [17] . Thus, in light of the availability of other effective treatment options for RA, IL-17 inhibitors are currently not a therapy option for this indication. It has been speculated that IL-17 and TNF inhibition might be of different relevance in RA dependent on the phase (early vs late) of the disease [18] and/or that RA patients might respond to IL-17 inhibition in case of previous TNF failure because elevated IL-17 serum levels have been described in TNF-failure patients [19] . However, such assumptions are currently not supported by any clinical data.
The anti-IL-17 inhibitor secukinumab failed also for the treatment of Crohn's disease, with no difference in efficacy compared with placebo treatment but with more side effects [20] .
In contrast, IL-17 inhibition seems to be more effective than TNF blocker therapy [21] , and even better than IL-12/-23 inhibition with the anti-p40 antibody ustekinumab [22] , for the treatment of psoriasis. It seems, however, that IL-23 blockade with an anti-p19 antibody has a comparable effect in psoriasis [23] to anti-IL-17 agents. Thus, IL-17 inhibition (most likely together with anti-IL23 p19 antibodies) will probably be the first drug of choice for moderate to severe psoriasis; treatment failure will be less frequent (compared with axSpA) and therefore a switch to TNF blocker therapy or a combination with a TNF blocker therapy will be of limited clinical relevance.
Do TNF and IL-17 blockers have different effects on radiographic progression in axial SpA?
It has been shown that TNF blockers do not inhibit radiographic spinal progression in established AS if given over a period of 24 years [1] . This might be different if patients are treated earlier or long-term with TNF blockers. It has recently been shown in an uncontrolled analysis that in established AS patients treated with the IL-17 inhibitor secukinumab over 2 years, radiographic progression was slower [24] than the one seen in the earlier AS studies with TNF blockers. We know from animal studies that a relevant function of IL-17 is the stimulation of osteoclasts [25] , but more recently a possible effect of IL-17 on osteoblast differentiation has also been described in some models of arthritis [26, 27] , but not in all [28] . Thus more data are needed in the future about a possible differentiating effect between the two type of drugs on bone metabolism.
How should anti-TNF and anti-IL-17 treatment in axSpA be optimized?
Because of a similar efficacy of TNF inhibitors and IL-17 inhibitors in axSpA and because an ASAS40 response is reached in only about 4050% of AS patients treated (Table 1) , it is of great clinical relevance whether the same patients or different patients respond to TNF and IL-17 inhibition, whether potential responders can be identified before treatment, what the optimal strategy of switching is in a case of a non-response and, finally, whether a combination of both treatments is an option in some of the patients. These open questions include also the optimal sequence of the drugs, including the best first choice. Interestingly, currently almost no data are available to answer these questions. It has only been shown [2, 10] that AS patients who had been treated with a TNF blocker before, when this treatment was stopped for any reason, responded to anti-IL-17 treatment, although on a lower level compared with TNF-naïve patients.
Is the combination of TNF and IL-17 inhibition a potential treatment option?
Pre-clinical data indicate that IL-17 and TNF are synergistic under certain conditions for inflammation but also for cartilage and bone destruction, and that inhibition of both molecules simultaneously seems to be more effective than inhibition of just one [37, 38] . Also safety data are already available from treatment trials blocking both TNF and IL-17 simultaneously in patients with PsA and RA. Single antibodies have been developed that inhibit both TNF and IL-17 at the same time, either using a dual variable domain immunoglobulin, the Abbvie antibody ABT-122 [39, 40] or a bispecific antibody fusion protein, the Jannsen/Covagen antibody COVA322 [41] . The ABT-122 has been investigated in RA [39] and PsA [40] in comparison with placebo and in comparison with adalimumab. Of relevance for the discussion of potentially combining the two treatments, there were no unexpected safety signals in comparison with adalimumab alone or with placebo treatment after 1224 weeks in an RA and a PsA trial [39, 40] . It was calculated that a dosage of 120 mg every 2 weeks of this dual antibody, ABT-122, would be equivalent to 40 mg adalimumab every 2 weeks. However, it is less clear whether the concentration of the anti-IL-17 part was optimal and what the equivalent dose to a single anti-IL-17 antibody would be. Especially the high dose ABT-122 (240 mg every 2 weeks) was better than adalimumab alone in PsA regarding the ACR50 and ACR70 response, although this difference was statistically not significant, probably because of the rather small group size. The clinically relevant question of the efficacy of a dual (or bispecific) cytokine blockade in patients not responding fully to the blockade of only one cytokine could not, however, be answered with that study design. A study involving patients with an inadequate response to previous anti-TNF or anti-IL-17 therapy or a study with a possibility of switch to a dual or bispecific drug after the failure of a monospecific antibody (see also below) is needed in order to answer this question.
In another study (ClinicalTrials.gov ID: NCT02430909), patients with active RA are treated first with the TNF blocker certolizumab and after 8 weeks of treatment the anti-IL-17A + F monoclonal antibody bimekizumab from UCB or placebo is added while certolizumab pegol treatment is continued. Results from this trial, especially regarding safety, should become available soon because recruitment of patients has been completed.
How can these questions be addressed?
A rather simple way to address these questions would be by a crossover trial design (Fig. 1) . Active axSpA patients would be treated with either a TNF blocker or an IL-17 inhibitor. A larger proportion of the patients in these groups would then be switched to the other treatment, both responder and non-responder (in terms of remission achievement) patients. Including also the responder patients in a crossover treatment would help to answer the question whether the same or different patients respond to the two treatments. And finally, for a subgroup of non-responders to both TNF and IL-17 inhibitors given sequentially, a combination of anti-IL-17 and anti-TNF could be given in the third study phase. Potentially, a bispecific antibody against TNF and IL-17 can be used instead of a combination of two drugs in the final phase. In general, it would be of interest to know the efficacy of a bispecific antibody in patients not responding adequately to a monospecific antibody.
First information to answer these questions could be obtained by rather simple study designs that can then form the basis to calculate numbers for bigger studies. A sample size of 160 patients with axSpA randomized 1:1 to the treatment arms would be sufficient to demonstrate a statistically significant difference in the response (remission-defined as ASDAS inactive disease in line with the recent update of the treat-to-target recommendations for spondyloarthritis [42] ) rates at week 24 between patients who switched the drug because of nonresponse (no remission) at week 12 vs those who continued on the same drug. Based on the above mentioned studies with TNF and IL-17 inhibitors in axSpA/AS, remission at week 12 would be achieved by not more than 25% of the patients in both treatment groups. Therefore, at least 60 patients who did not achieve remission will be re-randomized to switch or not switch. We anticipate a significantly better response (remission) rate at week 24 in patients who switched the drug class (after initial nonresponse) compared with those who continued the same drug (about 25% vs 5%, respectively). Other important   FIG. 1 A proposal for the design of a strategy trial with TNF and IL-17 inhibitors in axial spondyloarthritis This clinical study should address questions of the optimal treatment strategy and of the value of combination therapy with TNF and IL-17 inhibitors in patients with axSpA. Good responders (reaching remission) are switched to the alternative antibody (to evaluate whether the same or different patients show a good response to IL-17 blockade and to TNF blockade). Bad responders (not reaching remission) are also switched to the alternative antibody, but for comparison one part of the non-responders continues treatment with the original antibody. All patients not reaching remission after the second step will then finally be treated with a combination of the two antibodies. a Instead of using a combination of two different antibodies, single dual or bispecific antibodies, blocking TNF and IL-17 at the same time, might be used.
endpoints, including response to a combined therapy with IL-17 blockers and TNF blockers at week 36 in those who do not achieve ASDAS inactive disease at week 24, would be studied in an exploratory way.
A double-blind design of the study would be optimal. This would be the first step to learn more about the (possibly) different potential of these two treatments for axSpA. Biomarkers should be collected during such a trial. Subsequently, clinical and biomarker data should be analysed to be able to select patients in the future for treatment with one of the drugs, and also to select patients who would benefit from switching or from a combination therapy. For the treating physician (rheumatologist) such data would be of great benefit to help him/her to exploit the potential of these two effective drugs in the treatment of axSpA patients optimally.
Conclusion
Postulating a comparable efficacy of the TNF blockers and the IL-17 inhibitors on disease activity in axial SpA patients on the group level, the questions about specific sub-groups of patients responding to one or the other of the two treatments, about the sequence of these drugs in a treatment algorithm and about the potential of a combination therapy can only be answered if addressed in specific treatment trials, such as the one proposed by us in this article. Available pre-clinical data do not offer sufficient information on this. These questions are especially of interest for the treatment of axial SpA because there are no other treatment options than TNF and IL-17 inhibition after failure of conventional treatment.
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